• Kane Biotech retained DNA Advisors as exclusive financial adviser to run a strategic review aimed at boosting shareholder value.
• Review will assess options including partnerships, financing, commercial collaborations, acquisitions, business development, or other corporate transactions.
• Process will run alongside execution of 2026 commercial rollout for revyve antimicrobial wound gel products in the US and Canada.
• No timetable was set for completion; updates are expected only if the board selects a specific course of action.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kane Biotech Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.